TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Heart Association’s 2026 scientific meeting is scheduled to feature two trials of intensive blood-pressure control in groups excluded from SPRINT: ischemic stroke survivors and higher-risk adults with type 2 diabetes. Both studies test a systolic target below 120 mmHg; their results had not yet been reported in the source material.
The American Heart Association’s 2026 scientific meeting is scheduled to feature two late-breaking trials testing intensive blood-pressure control in patient groups excluded from the landmark SPRINT study: ischemic stroke survivors and higher-risk adults with type 2 diabetes. The trials, OPTIMAL-Stroke and OPTIMAL-Diabetes, will test a systolic blood-pressure target below 120 mmHg; results were not available in the report published ahead of the meeting.
Both studies are listed among the meeting’s first late-breaking presentations on Saturday, Nov. 7. According to MedPage Today’s preview, each trial enrolled people whose systolic blood pressure was between 130 and 180 mmHg at the start and examined intensive lowering for cardiovascular protection. OPTIMAL-Stroke focuses on people who have survived an ischemic stroke, while OPTIMAL-Diabetes studies higher-risk participants with type 2 diabetes.
The meeting’s main scientific sessions are scheduled to run Nov. 7-9 in Chicago, with selected sessions livestreamed. Expanded programming began Friday, Nov. 6. The trials are expected to address gaps in evidence following SPRINT, which excluded both groups. The source report describes the presentations as forthcoming and does not provide their methods in detail, participant numbers, safety findings or clinical outcomes.
The blood-pressure studies are part of a broad program, not the only major topics highlighted in the preview. Other scheduled presentations include STREAM, a trial examining whether older adults without cardiovascular disease who take statins face risk if they stop; longer follow-up of trials of invasive treatment for stable ischemic heart disease; and studies of inflammation, lipoprotein(a), pacing, atrial fibrillation, sleep apnea and AI-enabled smartwatch ECGs. These are scheduled items, not results reported in the preview.
Evidence Beyond SPRINT’s Participants
SPRINT influenced U.S. hypertension guidance, and evidence from its participants helped shape changes to how high blood pressure is defined nationally in 2017, according to the MedPage Today report. But trial findings do not automatically apply to populations that were excluded. Results from stroke survivors and people with type 2 diabetes could help clinicians and guideline writers judge whether an intensive target is appropriate for these groups.
The target below 120 mmHg is more intensive than simply asking whether blood pressure should be treated. The practical question is whether aiming that low offers cardiovascular protection for these particular patients and what trade-offs may accompany it. The preview provides no results on benefits or harms, so it cannot establish that the target should change care. The trials’ findings, including how their participants and outcomes compare with clinical practice, will be needed before drawing conclusions.
Products Worth Considering
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings Sleep Under-Mattress Sleep Tracking Pad
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How the Trials Extend SPRINT
SPRINT was a landmark study of intensive blood-pressure treatment, but the two groups now being examined were outside its enrolled population. The AHA meeting preview identifies this exclusion as the reason OPTIMAL-Stroke and OPTIMAL-Diabetes may fill important evidence gaps. The trials test a similar systolic goal in different clinical populations rather than simply repeating one study in the same group.
The preview was published by MedPage Today on Nov. 6, 2026, before the meeting presentations. It says the national redefinition of hypertension followed SPRINT more than a decade earlier, but does not give further detail on the guideline changes or on how the new studies were designed. Their findings should be read as new evidence to evaluate, not as proof that existing treatment recommendations have already changed.
“both important patient groups excluded from the SPRINT trial”
— MedPage Today, in its AHA meeting preview
Results and Clinical Effects Await
The source material is a meeting preview published before the presentations. It does not report trial results, participant counts, follow-up periods, adverse events or the size of any cardiovascular benefit. It is also not clear from the preview how the studies define “higher-risk” diabetes participants, how blood pressure was measured or whether the trials reached their intended enrollment and follow-up targets.
Until results are presented and reviewed, it remains unknown whether a target below 120 mmHg improves outcomes in either group, whether benefits differ between the trials, or what risks and treatment burdens may accompany intensive lowering. The preview does not announce any change to clinical guidelines or recommend that patients alter their blood-pressure treatment.
Presentations Begin Saturday
OPTIMAL-Stroke and OPTIMAL-Diabetes are scheduled for presentation on Saturday, Nov. 7, during the AHA’s early late-breaking sessions. The meeting’s main sessions continue through Monday, Nov. 9, with select presentations available by livestream. The next reporting milestone is the release and discussion of the trials’ data at the meeting.
Readers should look for the full results, including study design, outcomes, safety information and limitations, before judging their clinical implications. Whether the findings are later reflected in guidelines or practice remains to be seen; the premeeting report does not specify a timetable for that review.
Key Questions
What are OPTIMAL-Stroke and OPTIMAL-Diabetes?
They are two trials scheduled for presentation at the AHA meeting. One studies intensive blood-pressure control in ischemic stroke survivors; the other studies higher-risk adults with type 2 diabetes.
What blood-pressure target are the trials testing?
Both are described as testing a systolic blood-pressure target of less than 120 mmHg for cardiovascular protection among participants who started with readings from 130 to 180 mmHg.
Why are these groups being studied separately from SPRINT?
The AHA meeting preview says people with prior ischemic stroke and the higher-risk diabetes group were excluded from SPRINT. The new studies are intended to provide evidence about intensive targets in those populations.
Have the trials shown that intensive control works?
The source report was published before the scheduled presentations and gives no outcome results. It therefore does not establish whether the target improves cardiovascular outcomes or what risks may be associated with it.
When will the trial findings be presented?
Both trials are listed for Saturday, Nov. 7, 2026, during the American Heart Association’s scientific meeting in Chicago. Selected sessions are scheduled to be livestreamed.
Source: medpagetoday.com
